Research

Our pick of COVID-19-related cross-sectional case control studies from the scientific press for December 2022.

In order to support and develop expertise in bridging the gap between neuroscience and clinical knowledge the EAN Board has created a Scientific Panel on Neuroscience/Translational Neurology.

Our authors of the month report the results of a multicentre phase-3 clinical trial exploring efficacy and safety of Lecanemab in patients with early AD over a follow-up period of eighteen months.

Our authors of the month conducted a retrospective study of the potential association between COVID-19 and seizures or epilepsy in the six months after infection, using an electronic health records network of 81 million people.

A new publication in the European Journal of Neurology describes the process of developing and launching the EAN guideline prioritisation procedure.

EAN Guideline production group (GPG) reports from this year's Guidelines International Network conference in Toronto.

Our research paper of the month presents the results of the Endovascular Treatment for Acute Basilar-Artery Occlusion (ATTENTION) trial; a multicentre, prospective, randomised and open-label trial, conducted in 36 Chinese centres.

The authors of our Covid paper of the month conducted this cross sectional study in southern Germany involving people aged 18–65, confirming the existence of a considerable burden of self-reported post-acute symptom clusters

The EAN is pleased to announce we are developing the EAN Strategic Research Agenda to address current gaps and set priority areas for new clinically relevant research.

This month we have selected the guidelines dedicated to the invasive therapeutic pathways for Parkinson's disease, published jointly by the EAN and the Movement Disorder Society-European Section.

Our paper of the month for October investigates vestibular function in patients with dizziness, vertigo and postural symptoms following COVID-19 vaccination.

The 2017 McDonald criteria showed higher sensitivity, lower specificity, and similar accuracy in predicting clinically definite multiple sclerosis compared to 2010 McDonald criteria, while shortening time to its diagnosis.

Insidious disability accrual starts already in the earliest phases of multiple sclerosis and becomes dominant over the disease course, suggesting an ongoing process of inflammation and/or degeneration secondary to disease burden.

Epstein-Barr virus infection is the strongest known risk factor for the development of multiple sclerosis, and it precedes preclinical manifestation of the disease suggesting a possible causal role

In multiple sclerosis, an impairment of the glymphatic system may contribute to pathology accrual in the central nervous system and disability progression.